Dianthus Therapeutics Inc (DNTH)

NASD · Healthcare · Biotechnology · USA

Dianthus Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies for severe autoimmune diseases. Its lead candidate, claseprubart, is a monoclonal antibody targeting C1s complement protein administered via self-administered subcutaneous injections. The company also develops DNTH212, a bifunctional fusion protein targeting plasmacytoid dendritic cells and B cell function for autoimmune indications.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Dianthus Therapeutics Inc stock.

Our verdict on DNTH

Overvalued: intrinsic value $6.60 per share, market price $86.98, margin of safety -1217.0% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $6.60; the price of $86.98 is 1217% above that value.

ETFs with the most weight in DNTH

17 more funds hold it; the full list is part of the paid plan.

More on DNTH

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than DNTH in Biotechnology

110 more in this industry show a wider margin of safety.

Is DNTH undervalued or overvalued?

DNTH is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $6.60; the price of $86.98 is 1217% above that value.

What is the intrinsic value of DNTH?

$6.60 per share (as of the 2026-11-17 close), against a market price of $86.98. That is a margin of safety of -1217.0%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.